

Curriculum Vitae Eva Maria König, PhD

PERSONAL DATA

<i>Name</i>	Eva Maria König, née Putz
<i>Citizenship</i>	Austria
<i>Date of birth</i>	6 th of August 1983
<i>Place of birth</i>	Bregenz, Austria
<i>Current work address</i>	Medical University of Vienna, Center for Physiology and Pharmacology Institute of Pharmacology, Waehringer Strasse 13A, A-1090 Vienna, Austria
<i>Marital status</i>	Married, two daughters (born 12/2017 and 06/2023)
<i>ORCID</i>	https://orcid.org/0000-0002-9990-4477
<i>Homepage</i>	https://evamkoenig727.wixsite.com/putz-koenig-lab
<i>E-mail</i>	eva-maria.koenig@meduniwien.ac.at

FIELDS OF RESEARCH

<i>Keywords</i>	immunology, tumor immunology, cell biology, natural killer (NK) cells, immunoediting, tumor evolution, cytokines, JAK/STAT/SOCS signaling, pharmacology, extracellular matrix, invasion and metastasis, leukemia, melanoma, cellular immunotherapy
-----------------	--

EDUCATION

<i>2007-2013</i>	PhD thesis (N094) at the Medical University of Vienna (MUW) under the supervision of Univ.-Prof. Dr. V. Sexl: Impact of IFNAR1 and STAT1-S727 on NK cell activity and tumor surveillance
<i>2006-2007</i>	Diploma thesis at the Max Perutz Laboratories, Vienna, under the supervision of a.o.Univ.-Prof. Dr. F. Pittner: Studies to develop a meat freshness sensor based on nanotechnology
<i>2001-2007</i>	Diploma studies of Chemistry at the University of Vienna
<i>1994 – 2001</i>	High school BG Bregenz Blumenstraße

EMPLOYMENTS

<i>2024 – current</i>	Principal Investigator at the Institute of Pharmacology, MUW, Vienna
<i>2019 – 2023</i>	Principal Investigator at the St. Anna Children's Cancer Research Institute, Vienna
<i>Apr. 2017 – Mar. 2018</i>	Max Perutz Laboratories / Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratories of Prof. Thomas Decker (MFPL) and Prof. Veronika Sexl (Vetmeduni)
<i>Mar. 2015 – Feb. 2017</i>	QIMR Berghofer Institute of Medical Research (QLD, Australia): Post-doctoral fellow in the laboratory of Prof. Mark Smyth
<i>Sept. 2013 – Feb. 2015</i>	Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratory of Prof. Dr. V. Sexl
<i>2007-2013</i>	MUW/Vetmeduni Vienna (Austria): Pre-doctoral fellow in the laboratory of Prof. Dr. V. Sexl, supervision of trainees and diploma students
<i>Sept.-Oct. 2005</i>	Tecnonuclear (Buenos Aires, Argentina): internship

ACADEMIC RECOGNITION

<i>Grants</i>	2024: DOC fellowship for my PhD student Faith David, Austrian Academy of Sciences (98,160 €; “The role of serine/threonine kinase 38 (STK38(L)) in NK cells – A promising novel target for cancer immunotherapy”, 09/2024-07/2026; <u>PhD and project supervision</u>) 2021: Stand-Alone Project, Austrian Science Fund (FWF P34832; 399,640 €; “Non-canonical STAT1 signaling in natural killer cells”; 01/2022-06/2027; <u>project lead</u>) 2021: Fellingner Cancer Research Grant (25,000 €, “Uncovering immune evasion mechanisms of leukemic cells from natural killer cells”, 07/2021-06/2022, <u>project lead</u>) 2021: DOC fellowship for my PhD student Michelle Buri, Austrian Academy of Sciences (115,500 €; “How do leukemic cells escape natural killer cell-mediated surveillance? Uncovering novel immune evasion mechanism(s)”; 08/2021-06/2024; <u>PhD and project supervision</u>) 2019: Science Communication Project, Austrian Science Fund (FWF WKP 132-B: 49,083 €; “Art4Science”, 05/2020-04/2022, <u>project lead</u>) 2018: Stand-Alone Project, Austrian Science Fund (FWF P32001-B; 341,760 €; “Finding tumor immune evasions strategies by cellular barcoding”; 03/2019-09/2023, <u>project lead</u>) 2014: Erwin Schrödinger Fellowship, Austrian Science Fund (FWF J3635; 156,940 €; “NLRP1 and NLRP3 in T and NK cell immunity”; 02/2015-03/2018, <u>project lead</u>) 2008: DOC-ffORTE, Austrian Academy of Science (60,000 €; “STAT1 Serine727 – Key Regulator for NK Cell-Mediated Cytotoxicity and Tumor Surveillance”; 01/2010-12/2011; <u>project lead</u>)
<i>Awards</i>	2022: Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR) 2022: Best talk at the 14th ÖGMBT Annual Meeting, Vienna, Austria 2014: Poster prize at the 6th ÖGMBT Annual Meeting, Vienna, Austria 2014: Armin Tschernek von Seysenegg Prize, Gesellschaft der Freunde der VUW 2013: EFIS scholarship, 2nd Meeting of Mid-Europ. Soc. f. Immunol. and Allergol., Croatia 2011: EFIS-EJI scholarship for EMBO - Signaling in the Immune System Meeting in Siena, Italy 2009: Poster prize at the Natural Killer Cell Symposium in Freiburg, Germany
<i>Oral Presentations</i>	2023: - Seminar at the Fondazione Ri.MED, Palermo, Italy - CACB Seminar at the Center for Anatomy and Cell Biology, MUW, Austria 2022: - Keynote lecture at the 26th Annual Meeting of the APHAR in Graz, Austria - 14th ÖGMBT Meeting, Vienna, Austria - Series “Being up to date in cancer biology” at the VetMedUni Vienna, Austria 2021: Karl Landsteiner Lunchtime seminar, virtual 2020: Science Meeting at the Institute of Physiology, Medical University of Vienna, Austria 2019: LBI for Hematology and Oncology KickOff Meeting, Austria 2014: NK2014 Meeting, Germany 2013: 2nd Meeting of Middle-Europ. Soc. f. Immunol. & Allergol. Croatia 2013: 19th Scientific Symposium of APHAR, Austria 2010: Annual Meeting of the Austrian Society for Allergology and Immunology (ÖGAI), Vienna, Austria 2008: 4th PhD Symposium, Austria
<i>Memberships</i>	APHAR (Austrian Pharmacological Society, since 2008) EATI (European Academy of Tumor Immunology, since 2016) OEGAI (Austrian Society for Allergology and Immunology, since 2011) OEGMBT (Austrian Association of Molecular Life Sciences and Biotechnology, since 2013)
<i>Peer-Review activities</i>	<i>Journals:</i> Animal Biotechnology, Cancer Research, Frontiers in Immunology, Journal of ImmunoTherapy of Cancer, Journal of Medicinal Chemistry, Molecules, Nature Communications, OncoImmunology, PlosOne, Trends in Immunology; <i>Funding Bodies:</i> Children’s Cancer and Leukaemia Group (CCLG), Grace Kelly Childhood Cancer Trust
<i>Editorial activities</i>	2021-2022: Topic editor of “Drivers of Innate Lymphoid Cell Plasticity” in Frontiers in Immunology
<i>Collaboration partners</i>	Emilio Casanova, Matthias Farlik, Thorsten Füreder, Dietmar Herndler-Brandstetter, Johannes Huppa, Xaver König, Christoph Minichsdorfer, Herwig Moll, Shinya Sakaguchi, Isabella Salzer, Gernot Schabbauer, Charlotte Zajc, Eva Zebelin-Brandl (MUW, Austria); Martin Distel, Manfred Lehner, Sabine Strehl, George Cresswell, etc. (CCRI, Austria); Dagmar Gotthardt, Veronika Sexl (Vetmeduni, Austria); Dagmar Stoiber-Sakaguchi, Agnieszka Witalisz-Siepracka (KL University Krems, Austria); Anna Obenaus (IMP, Austria); Michael Traxlmayr (BOKU, Austria); Tobias Bald, Dillon Corvino (University of Bonn, Germany); Leila Perié (Institut Curie, France); Ton Schumacher (NKI, The Netherlands); Heidi Harjunpää (University of Helsinki, Finland); Eric Kowarz, Rolf Marschalek (University of Frankfurt, Germany); Melissa Elliott, Todd A. Fehniger (Washington University in St. Louis, USA); Debby Hynx, Fengyuan Tang (University of Basel, Switzerland); Juming Yan (Xuzhou Medical University, China)

SCIENCE COMMUNICATION ACTIVITIES

<i>Science Communication</i>	X (former Twitter): Tumor Immunoediting Lab (@TIE_Lab) since 2020: Art4Science project (https://www.art4science.at/) 2019-2023: Lange Nacht der Kinderkrebsforschung, CCRI 2018: BE OPEN Science & Society Festival of the FWF
<i>Teaching</i>	2024 WS: MUW: SSM1 (SE), Basic lecture in the PhD program MolSignTrans (VO), JC (SE), TS (SE) 2020 WS: MUW: Spot Lights on Paediatric Cancer Research (SE) 2017 SS: Vetmeduni Vienna: Neue Therapieansätze in der Tumorthherapie (SE) 2016: QIMR Berghofer Institute, Australia: High school work experience program (SE+PR) 2014 WS: MUW: Basic seminar in the PhD program Inflammation and Immunity (SE) 2007 SS: University of Vienna: Laboratory Course C + Molecular Biology II (PR)
<i>Supervision</i>	Bachelor student: L. Sippl (2023) Master students: K. Kos (2016), S. Stofner (2021), A. Dupanovic (2023), N. Schindler (2024) PhD students: M.C. Buri (2020-current), F.O. David (2021-current) (MUW, N094) Postdoctoral fellows: Dr. C. Zajc (2023-current, University of BoKu/MUW, mentor through ESPRIT, FWF), Dr. H. Baik (2019-2023), Dr. B. Kovacic (2019-2020)
<i>Extracurricular activities</i>	PhD committee member of J. List (Vetmeduni, 2022-current), Master and PhD thesis reviewer and examiner (MUW, VetMedUni and the University of Maastricht)
<i>Meetings – Poster Presentations (excerpt)</i>	2016: International Congress of Immunology (ICI), Melbourne, Australia: <u>E.M. Putz</u> , F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. “The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance” 2015: Immunotherapy@Brisbane, Brisbane, Australia: <u>E.M. Putz</u> , F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. “The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance” 2015: 1 st Australian Innate Lymphocyte Symposium, Melbourne, Australia: <u>E.M. Putz</u> , A. Majoros, D. Gotthardt, T. Decker and V. Sexl. “Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity” 2012: Natural Killer cell Symposium NK2012, Heidelberg, Germany: <u>E.M. Putz</u> , D. Gotthardt, D. Stoiber, T. Decker and V. Sexl, “Stat1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance” 2011: EMBO Conference: Signaling in the Immune System, Siena, Italy: <u>E.M. Putz</u> , E.M. Zebedin-Brandl, M. Prchal, T. Decker and V. Sexl, “STAT1 Serine727 – License to Kill” 2009: Natural Killer cell Symposium NK2009, Freiburg, Germany: <u>E.M. Putz</u> , E.M. Zebedin, A. Csiszar, M. Prchal, T. Decker, P. Kovarik and V. Sexl, “STAT1-Serine727 – Key regulator for NK cell mediated cytotoxicity and tumor surveillance” 2009: 15 th International Summer School on Immunology (FEBS), Hvar, Croatia: <u>E.M. Putz</u> , E. Zebedin, A. Csiszar, M. Prchal, A. Berger, T. Decker, P. Kovarik and V. Sexl, “STAT1-S727 - Key regulator for NK cell-mediated cytotoxicity and tumor surveillance”

MAIN AREAS OF RESEARCH

For the last 17 years, I have worked in the field of tumor immunology, starting as a PhD student in the laboratory of Veronika Sexl (MUW and Vetmeduni Vienna) and proceeding as a postdoctoral fellow in the laboratory of Mark Smyth at the QIMR Berghofer Institute of Medical Research in Brisbane (Australia).

The focus of my studies has always been to increase our knowledge about how to improve the anti-tumor functions of cytotoxic immune cells such as natural killer and T cells. By using gene-modified mice, a multitude of *in vivo* tumor models and an extensive range of *in vitro* assays (e.g. multi-color flow cytometry, molecular biology and functional assays, cellular barcoding, primary cell transduction, gene knockdown and knockout, mass spectrometry, etc.) I have contributed to the discovery of exciting novel ways of enhancing NK cell-mediated tumor surveillance (e.g. blocking CDK8-mediated STAT1-S727 phosphorylation or CIS-mediated downregulation of IL-15 signaling) and highlighted the potential drawback of drugs that interfere with NK cell migration (heparanase inhibitors) or T cell function (PI3Kδ inhibitors).

I collaborated with highly ranked scientists all over the world and published 1 book chapter, 6 reviews and 34 original peer-reviewed papers, some of which had to be corrected or retracted due to concerns of data fabrication by Mark J. Smyth. Please see [here](#) for more information and be assured that I had no part in scientific misconduct at any time.

PUBLICATIONS (published under my maiden name E.M. Putz)

citations: 2489; h-index: 25

1. M.C. Buri, M.R. Shoeb, A. Bykov, P. Repiscak, H. Baik, A. Dupanovic, F.O. David, B. Kovacic, F. Hall-Glenn, S. Dopa, J. Urbanus, L. Sippl, S. Stofner, D. Emminger, J. Cosgrove, D. Schinnerl, A.R. Poetsch, M. Lehner, X. Koenig, L. Perié, T.N. Schumacher, D. Gotthardt, F. Halbritter, E.M. Putz. Natural killer cell-mediated cytotoxicity shapes the clonal evolution of B cell leukaemia. **Cancer Immunology Research**, PMID: 39642167, Dec. 2024
2. J. Zehenter*, M. Prchal-Murphy*, M. Fischer, A. Pirabe, M. Themanns, B. Afrashteh, E.M. Putz, K. Kollmann, J. Basilio, M. Salzmann, W. Strohmaier, G. Kruppl, A. Farr, V. Sexl, M. Freissmuth, E.M. Zebedin-Brandl. Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation. **Frontiers in Pharmacology**, in press
3. A. Witalisz-Siepracka, C.-M. Denk, B. Zdársky, L. Hofmann, S. Edtmayer, T. Harm, S. Weiss, K. Heindl, M. Hessenberger, S. Summer, S. Dutta, E. Casanova, G.J. Obermair, B. Györfy, E.M. Putz, H. Sill and D. Stoiber. STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance. **Frontiers in Immunology**, PMID: 39034990, Jul. 2024
4. J. List, J. Gattringer, S. Huszarek, S. Marinovic, H.A. Neubauer, P. Kudweis, E.M. Putz, R. Hellinger, D. Gotthardt. Boosting the anti-tumor activity of natural killer cells by caripe 8 - A Carapichea ipecacuanha isolated cyclotide. **Biomedicine & Pharmacotherapy**, PMID: 38976957, Jul. 2024
5. E. Lilliu*, B. Hackl*, E. Zabrodskaja, S. Gewessler, T. Karge, J. Marksteiner, J. Sauer, E.M. Putz, H. Todt, K. Hilber, X. Koenig. Cell size induced bias of current density in hypertrophic cardiomyocytes. **Channels**, PMID: 38836323, Jun./Dec. 2024
6. I.M. Saldana-Guerrero*, L.F. Montano-Gutierrez*, K. Boswell, C. Hafemeister, E. Poon, L.E. Shaw, D. Stavish, R.A. Lea, S. Wernig-Zorc, E. Bozsaky, I.S. Fetahu, P. Zoescher, U. Pötschger, M. Bernkopf, A. Wenninger-Weinzierl, C. Sturtzel, C. Souilhol, S. Tarelli, M.R. Shoeb, P. Bozatz, M. Rados, M. Guarini, M.C. Buri, W. Weninger, E.M. Putz, M. Huang, R. Ladenstein, P.W. Andrews, I. Barbaric, G.D. Cresswell, H.E. Bryant, M. Distel, L. Chesler, S. Taschner-Mandl, M. Farlik, A. Tsakiridis, F. Halbritter. **Nature Communications**, PMID: 38702304, May 2024
7. D. Yuan, J. Hu, X. Ju, E.M. Putz, S. Zheng, G. Sun, S. Koda, Z. Xu, W. Nie, S. Shao, Y. Chen, R. Tang, K.-Y. Zheng, J. Yan. NMDAR antagonists suppressed tumor progression by regulating tumor-associated macrophages. **PNAS**, PMID: 37967215, Nov. 2023
8. B. Hackl, E. Zabrodskaja, S. Gewessler, E. Liliu, E.M. Putz, A. Kiss, B. Podesser, H. Todt, R. Ristl, K. Hilber, X. Koenig. The type of suture material affects transverse aortic constriction-induced heart failure development in mice: a repeated measures correlation analysis. **Frontiers Cardiovascular Medicine**, PMID: 37795481, Sep. 2023
9. S. Grissenberger, C. Sturtzel, A. Wenninger-Weinzierl, B. Radic-Sarikas, E. Scheuringer, L. Bierbaumer, V. Etienne, F. Némati, S. Pascoal, M. Tözl, E. Tomazou, M. Metzelder, E.M. Putz, D. Decaudin, O. Delattre, D. Surdez, H. Kovar, F. Halbritter, M. Distel. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-X_L inhibition against Ewing sarcoma. **Cancer Letters**, PMID: 36462556, Feb. 2023
10. T. Fuereder, C. Minichsdorfer, M. Mittlboeck, C. Wagner, G. Heller, E.M. Putz, F. Oberndorfer, L. Müllauer, M.-B. Aretin, C. Czerny, U. Schwarz-Nemec. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prespective phase I/II study. **Oral Oncology**, PMID: 34844042, Jan. 2022
11. B. Salzer, C.M. Schueller, C.U. Zajc, T. Peters, M.A. Schoeber, B. Kovacic, M.C. Buri, E. Lobner, O. Dushek, J.B. Huppa, C. Obinger, E.M. Putz, W. Holter, M.W. Traxlmayr, M. Lehner. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. **Nature Communications**, PMID: 32820173, Aug. 2020
12. D. Prinz, K. Klein, J. List, V.M. Knab, I. Menzl, N. Leidenfrost, G. Heller, B. Polić, E.M. Putz, A. Witalisz-Siepracka, V. Sexl, D. Gotthardt. Loss of NKG2D in Murine NK Cells Leads to Increased Perforin Production Upon Long-Term Stimulation With IL-2. **European Journal of Immunology**, PMID: 32052406, Feb. 2020
13. D. Gotthardt, J. Trifinopoulos, V. Sexl, E.M. Putz. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. **Frontiers in Immunology**, PMID: 31781102, Nov. 2019
14. E. Porpaczy*, S. Tripolt*, A. Hoelbl-Kovacic*, B. Gisslinger, Z. Bago-Horvath, E. Casanova-Hevia, T. Decker, S. Fajmann, D.A. Fux, S. Gueltekin, G. Heller, H. Herkner, T. Kolbe, E.M. Putz, C. Kornauth, M. Mueller, M. Prchal-Murphy, A.-I. Schiefer, C. Schneckenleithner, C. Skrabs, W.R. Sperr, B. Strobl, P. Valent, R. Kralovics, L. Muellauer, I. Simonitsch-Klupp, E. Cappier, E. Raffoux, J.-J. Kiladjian, M.-T. Krauth, P.B. Staber, G. Greiner, G. Hoermann, U. Jaeger*, H. Gisslinger* and V. Sexl*. Aggressive B-cell Lymphomas in Patients With Myelofibrosis Receiving JAK1/2 Inhibitor Therapy. **Blood**, PMID: 29907599, Aug. 2018
15. K. Nakamura, S. Kassem, A. Cleynen, M.-L. Chrétien, C. Guilleray, E.M. Putz, T. Bald, I. Förster, S. Vuckovic, G.R. Hill, S.L. Masters, M. Chesi, P.L. Bergsagel, H. Avet-Loiseau, L. Martinet* and M.J. Smyth*. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. **Cancer Cell**, PMID: 29551594, Mar. 2018
16. A. Witalisz-Siepracka*, D. Gotthardt*, M. Prchal-Murphy, Z. Didara, I. Menzl, D. Prinz, L. Edlinger, E.M. Putz, V. Sexl. NK cell-specific CDK8 deletion enhances antitumor responses. **Cancer Immunology Research**, PMID: 29386186, Jan. 2018
17. D. Mittal, D. Vijayan, E.M. Putz, A. Roman Aguilera, K. Markey, J. Straube, S. Kazakoff, S. Nutt, K. Takeda, G. Hill, N. Waddell, and M.J. Smyth. NK cell suppression of metastasis partially requires CD103⁺ Batf3-dependent dendritic cells and interleukin-12. **Cancer Immunology Research**, PMID: 29070650, Oct. 2017

PUBLICATIONS (continued)

18. E.M. Putz, A. Mayfosh, K. Kos, D.S. Barkauskas, L. Town, K.J. Goodall, D.Y. Yee, I.K.H. Poon, N. Baschuk, F. Souza-Fonseca-Guimaraes, M. Hulett* and M.J. Smyth*. Natural killer cell heparanase controls tumor invasion and immune surveillance. *Journal of Clinical Investigations*, PMID: 28581441, June 2017, **Retraction**, Jul. 2024
19. E.M. Putz, C. Guillerey, K. Kos, K. Stannard, K. Miles, R.B. Delconte, K. Takeda, S.E. Nicholson, N. D. Huntington, M.J. Smyth. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. *Onc Immunology*, PMID: 28344878, Feb. 2017
20. R. Klose, E. Krzywinska, M. Castells, D. Gotthardt, E.M. Putz, C. Kantari-Mimoun, N. Chikdene, A.K. Meinecke, K. Schrödter, I. Helfrich, J. Fandrey, V. Sexl, C. Stockmann. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. *Nature communications*, PMID: 27538380, Aug. 2016
21. E.M. Putz, A. Majoros, D. Gotthardt, M. Prchal-Murphy, E.M. Zebedin-Brandl, D.A. Fux, A. Schlattl, R.D. Schreiber, S. Carotta, M. Müller, C. Gerner, T. Decker* and V. Sexl*. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. *Onc Immunology*, PMID: 27757297, May 2016
22. R.B. Delconte*, T.B. Kolesnik*, L.F. Dagley*, J. Rautela, W. Shi, E.M. Putz, K. Stannard, J.G. Zhang, C. Teh, M. Firth, T. Ushiki, C. Andoniou, M.A. Degli-Esposti, P.P. Sharp, C.E. Sanvitale, G. Infusini, N.P. Liao, E.M. Linossi, C.J. Burns, S. Carotta, D.H. Gray, C. Seillet, D.S. Hutchinson, G.T. Belz, A.I. Webb, W.S. Alexander, S.S. Li, A.N. Bullock, J.J. Babon, M.J. Smyth, S.E. Nicholson*, N.D. Huntington*. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Nature Immunology*, PMID: 27213690, May 2016; **Correction**, Dec. 2023
23. D. Gotthardt, E.M. Putz, E. Grundschober, M. Prchal-Murphy, E. Straka, P. Kudweis, G. Heller, Z. Bago-Horvath, A. Witalisz-Siepracka, A.A. Cumaraswamy, P.T. Gunning, B. Strobl, M. Mueller, R. Moriggl, C. Stockmann, V. Sexl. STAT5 is a key regulator in NK cells and acts as molecular switch from tumor surveillance to tumor promotion. *Cancer Discovery*, PMID: 26873347, Feb. 2016
24. Y. Krasnova, E.M. Putz, M.J. Smyth, F. Souza-Fonseca-Guimaraes. Bench to bedside: NK cells and control of metastasis. *Clinical Immunology*, PMID: 26476139, Oct. 2015
25. M. Prchal-Murphy*, A. Witalisz-Siepracka*, K.T. Bednarik, E.M. Putz, D. Gotthardt, K. Meissl, V. Sexl, M. Müller, B. Strobl. In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. *Onc Immunology*, PMID: 26451322, July 2015
26. P. Pathria, D. Gotthardt*, M. Prchal-Murphy*, E.M. Putz*, M. Holcman, M. Schleder, B. Grabner, I. Crncec, J. Svinka, M. Musteanu, T. Hoffmann, M. Filipits, W. Berger, V. Poli, L. Kenner, M. Bilban, E. Casanova, M. Müller, B. Strobl, E. Bayer, T. Mohr, V. Sexl, R. Eferl. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. *Onc Immunology*, PMID: 26137415, Jan. 2015
27. E.M. Putz, D. Gotthardt, V. Sexl. STAT1-S727 - the license to kill. *Onc Immunology*, PMID: 25941617, Dec. 2014
28. D. Gotthardt, M. Prchal-Murphy, C. Seillet, A. Glasner, O. Mandelboim, S. Carotta, V. Sexl, E.M. Putz. NK cell development in bone marrow and liver - site matters. *Genes & Immunity*, PMID: 25319498, Oct. 2014
29. D. Gotthardt, E.M. Putz, E. Straka, P. Kudweis, M. Biaggio, V. Poli, B. Strobl, M. Müller, V. Sexl. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. *Blood*, PMID: 25185262, Sept. 2014
30. G. Hoermann, K. Blatt, G. Greiner, E.M. Putz, A. Berger, H. Herrmann, S. Cerny-Reiterer, K.V. Gleixner, C. Walz, K. Hoetzenecker, L. Müllauer, A. Reiter, K. Sotlar, V. Sexl, P. Valent, M. Mayerhofer. CD52 is a molecular target in advanced systemic mastocytosis. *FASEB J.*, PMID: 24760752, Apr. 2014
31. E.M. Putz, M.A. Hoelzl, J. Baeck, Z. Bago-Horvath, C. Schuster, B. Reichholf, D. Kern, F. Aberger, V. Sexl, A. Hoelbl-Kovacic. Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. *Cancers*, PMID: 24473086, Jan. 2014
32. A. Berger, A. Hoelbl-Kovacic, J. Bourgeais, L. Hoefling, W. Warsch, E. Grundschober, I.Z. Uras, I. Menzl, E.M. Putz, G. Hoermann, C. Schuster, S. Fajmann, E. Leitner, S. Kubicek, R. Moriggl, F. Gouilleux, V. Sexl. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. *Leukemia*, PMID: 24263804, Nov. 2013
33. E.M. Putz, D. Gotthardt, G. Hoermann, A. Csiszar, S. Wirth, A. Berger, E. Straka, D. Rigler, B. Wallner, A.M. Jamieson, W.F. Pickl, E. Zebedin-Brandl, M. Müller, T. Decker and V. Sexl. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. *Cell Reports*, PMID: 23933255, Aug. 2013
34. A.D. Köprülü, R. Kastner, S. Wienerroither, C. Lassnig, E.M. Putz, O. Majer, B. Reutterer, V. Sexl, K. Kuchler, M. Müller, T. Decker and W. Ellmeier. The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection. *PLoS ONE*, PMID: 23544144, Mar. 2013
35. M. Prchal-Murphy*, E.M. Putz*, M. Freissmuth, V. Sexl and E. Zebedin-Brandl. Targeting PI3Kδ - One man's meat is another man's poison. *Onc Immunology*, PMID: 23482629, Jan. 2013

PUBLICATIONS (continued)

36. T. Mizutani*, N. Neugebauer*, E.M. Putz*, N. Moritz, O. Simma, E. Zebedin-Brandl, D. Gotthardt, W. Warsch, E. Eckelhart, H.P. Kantner, U. Kalinke, S. Lienenklaus, S. Weiss, B. Strobl, M. Müller, V. Sexl and D. Stoiber. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. ***Onc Immunology***, PMID:23170251, Oct. 2012
37. E.M. Putz, C. Schuster and V. Sexl. Bcl-2: Live and let die. ***Onc Immunology***, PMID: 22934270, Aug. 2012
38. E.M. Putz*, M. Prchal-Murphy*, O.A. Simma, F. Forster, X. Koenig, H. Stockinger, R.P. Piekorz, M. Freissmuth, M. Müller, V. Sexl and E. Zebedin-Brandl. PI3K δ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. ***PLoS ONE***, PMID: 22808277, Jul. 2012
39. E.M. Putz, E. Zebedin and V. Sexl. STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. (bookchapter, p. 187-204) in the book: Jak-Stat Signaling: From Basics to Disease, editors T. Decker and M. Müller; ***Springer***, Online: ISBN 978-3-7091-0891-8, Jun. 2012
40. C. Schuster*, A. Berger*, M.A. Hoelzl, E.M. Putz, A. Frenzel, O. Simma, N. Moritz, A. Hoelbl, B. Kovacic, M. Freissmuth, M. Müller, A. Villunger, L. Müllauer, A.I. Schmatz, E. Porpaczy, U. Jäger, D. Stoiber and V. Sexl. The cooperating mutation or “second hit” determines the immunological visibility towards MYC-induced murine lymphomas. ***Blood***, PMID: 21878673, Aug. 2011
41. A.A. Vitale, A.B. Pomilio, C.O. Cañellas, M.G. Vitale, E.M. Putz and J. Ciprian-Ollivier. In Vivo Long-Term Kinetics of Radiolabeled *N,N*-Dimethyltryptamine and Tryptamine. ***Journal of Nuclear Medicine***, PMID: 21622895, Jun. 2011
42. O. Simma, E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E.M. Putz, W.F. Pickl, T. Felzmann, M. Müller, T. Decker, V. Sexl and D. Stoiber. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. ***Cancer Research***, PMID: 19118004, Jan. 2009
43. E. Zebedin, O. Simma, C. Schuster, E.M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J.A. Schmid, W.F. Pickl, C. Baumgartner, P. Valent, R.P. Piekorz, M. Freissmuth and V. Sexl. Leukemic challenge unmasks a requirement for *PI3K δ* in NK-cell-mediated tumor surveillance. ***Blood***, PMID: 18684865, Aug. 2008

* ... contributed equally